Loading clinical trials...
Loading clinical trials...
AN OPEN-LABEL, RANDOMIZED, CONTROLLED PHASE 3 STUDY OF SIGVOTATUG VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB COMPARED WITH PEMBROLIZUMAB MONOTHERAPY AS FIRST-LINE TREATMENT IN PARTICIPANTS WITH PD-L1 HIGH (≥50% OF TUMOR CELLS EXPRESSING PD-L1), LOCALLY ADVANCED, UNRESECTABLE, OR METASTATIC NON-SMALL CELL LUNG CANCER (BE6A LUNG-02)
Conditions
Interventions
Sigvotatug Vedotin
Pembrolizumab
Locations
329
United States
Providence St. Jude Medical Center Virginia K. Crosson Cancer Center and Infusion Center
Fullerton, California, United States
Providence St. Jude Medical Center
Fullerton, California, United States
St. Jude Heritage Medical Group - Fullerton Plaza Multi-Specialty Clinic (Pulmonary Function Test)
Fullerton, California, United States
Intermountain Health Cancer Center Lutheran Hospital
Golden, Colorado, United States
Cancer Centers of Colorado St. Mary's Regional Hospital
Grand Junction, Colorado, United States
Intermountain Health St. Mary's Regional Hospital
Grand Junction, Colorado, United States
Start Date
July 23, 2025
Primary Completion Date
September 5, 2028
Completion Date
March 1, 2029
Last Updated
April 20, 2026
NCT06855771
NCT07431827
NCT06427941
NCT07164313
NCT06120140
NCT06253871
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions